Supplementary information for

"Activation of RXR/PPAR heterodimers by organotin environmental endocrine disruptors"

Albane le Maire, Marina Grimaldi, Dominique Roecklin, Sonia Dagnino, Valérie Vivat-Hannah, Patrick Balaguer and William Bourguet




Fig S1 Comparison of the interaction between RXR α LBD and organotins. Superposition of TBT-A (pink), TPT (triphenyltin, orange), TET (triethyltin, blue) and TOT (trioctyltin, green) in stick representation in the TBT binding pocket shown in white.




Fig S2 TBT activates RXR/PPAR α and RXR/PPAR δ heterodimers. (**A**) Stably transfected HELN PPAR α cells were incubated with increasing concentrations of GW327647, CD3254 or TBT to measure their effect on the transcriptional activity of the heterodimer formed by Gal4-PPAR α and endogenous RXR. (**B**) To measure the specific effect of the organotin on PPAR α and RXR, GW327647, CD3254 or TBT were also tested in the presence of saturating concentrations of RXR (CD3254; 0.1 μM) or PPAR α (GW327647; 1 μM) specific ligands. 100% activity corresponds to the activity obtained with 1 μM GW327647. (**C**) and (**D**) Same experiments with HELN PPAR δ cells and GW610724 as the PPAR δ specific agonist. To measure the specific effect of the organotin on PPAR δ and RXR, GW610724, CD3254 or TBT were tested in the presence of saturating concentrations of RXR (CD3254; 0.1 μM) or PPAR δ (GW610724; 0.1 μM) specific ligands.

 Table S1 Data collection and refinement statistics

P43212
64.03, 64.03, 111.88
30.77-1.90 (2.00-1.90) *
0.062 (0.455) *
25.9 (4.3) *
98.0 (97.2) *
8.8 (9.2) *
28.63-1.90
17, 579
19.0 / 22.5
1,960
1,676
26
166
25.2
24.2
21.6
33.2
0.011
1.206
95.4
4.1
0.5
0.0

^{*}Values in parentheses are for highest resolution shell.

Table S2 Comparison of the binding pocket properties in RXRα-agonists (9cis-RA and CD3254) and RXRα-organotins (TBT, TPT, TET and TOT) complexes and comparison of the agonist ligands and organotin compounds ability to bind and activate RXRα. Ligand volumes were calculated using Vega ZZ (Pedretti et al., 2004). Organotins were manually docked in the TBT binding pocket and the complexes were energy-minimized using REFMAC5 from the CCP4 suite (CCP4, 1994). Protein ligand contacts (cutoff 4.2Å) were evaluated using CONTACT (CCP4, 1994).

Ligand	Ligand	Total	Type of contacts	Activation and Binding	
	volume	contact	(covalent/vdw	EC ₅₀ of GAL-	IC ₅₀ for
	$(Å^3)$	numbers	/polar)	RXR activity	competition with
				(nM)	^[3H] 9cis-RA (μM)
TBT ^a	233	49	1 / 49 / 0	14.4 ^e	0.468 ^e
9cis-RA ^b	319	74	0 / 69 / 5	10.2 ^e	0.107 ^e
CD3254 ^c	352	107	0 / 100 / 7	$10.0^{\rm f}$	-
TPT^d	245	82	1/81/0	13.9 ^e	0.527 ^e
TET^d	131	21	(1) / 20 / 0	not detectable e	6.76 ^e
TOT^d	436	103	(1)/102/0	not detectable e	>10 ^e

^a The RXRα-TBT complex is described in this study.

^b PDB code 1FBY (Egea et al., 2000).

^c The structure of RXRα-CD3254 has been solved but not yet published (our results).

^d These complexes were modeled from the structure of RXR α -TBT complex. Number and type of contacts are in italics to emphasize that they are only estimations.

^e Nakanishi et al., 2005

f Nahoum et al., 2007

Supplementary METHODS

Preparation of stable PPAR cell lines. HGELN hPPARα, hPPARδ and hPPARγ cell lines were generated in two steps. Firstly, we generated the HGELN cell line by transfecting HeLa cells with the pGAL4RE-ERE-βGlob-Luc-SVNeo plasmid. Secondly, we transfected HGELN cells with pGAL4-PPAR-puro plasmids. pGAL4RE-ERE-βGlob-Luc-SVNeo contains a luciferase gene driven by a yeast activator GAL4 and an estrogen receptor binding site in front of the β-globin promoter and a neomycin phosphotransferase gene under the control of the SV40 promoter. In pGAL4-PPAR-puro (Seimandi et al, 2005), the encoded chimeric GAL4-PPAR proteins consists of 1-147 GAL4 amino acids followed by the human PPAR LBDs. (Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin.

References

CCP4. (1994) Collaborative Computational Project Number 4. *Acta Crystallogr D Biol Crystallogr*, **50**: 760-763

Egea, P.F., Mitschler, A., Rochel, N., Ruff, M., Chambon, P. and Moras, D. (2000) Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. *EMBO J.* **19**: 2592-2601

Nahoum, V., Perez, E., Germain, P., Rodriguez-Barrios, F., Manzo, F., Kammerer, S., Lemaire, G., Hirsch, O., Royer, C.A., Gronemeyer, H., de Lera, A.R. and Bourguet, W. (2007) Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. *Proc Natl Acad Sci U S A*, **104**: 17323-17328

Nakanishi, T., Nishikawa, J., Hiromori, Y., Yokoyama, H., Koyanagi, M., Takasuga, S., Ishizaki, J., Watanabe, M., Isa, S., Utoguchi, N., Itoh, N., Kohno, Y., Nishihara, T. and Tanaka, K. (2005) Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. *Mol Endocrinol*, **19**: 2502-2516

Pedretti, A., Villa, L. and Vistoli, G. (2004) Vega - An open platform to develop chemo-bio-informatics applications, using plug-in architecture and script" programming. *J.C.A.M.D.*, **18**: 167-173

Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, Vignon F, Nicolas JC, Balaguer P (2005) Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. *Anal Biochem* **344:** 8-15